About: Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL) Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

article

Attributes	Values
rdf:type	Item
description	article (en) wetenschappelijk artikel (nl) наукова стаття, опублікована в червні 2014 (uk) article scientifique publié en 2014 (fr) im Juni 2014 veröffentlichter wissenschaftlicher Artikel (de)
publication date	wds:Q58024649-B9CD6A40-B915-4DBA-8274-CEFF2805971C
publication date	2014-06-20 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q58024649-C972D11E-72EF-453A-AFF2-29140D102F30
language of work or name	English
author name string	wds:Q58024649-034FC7C8-428C-48A3-9EEC-A2B6A9D60849 wds:Q58024649-1530478A-F706-4DCB-888C-308F008FBBB3 wds:Q58024649-24DB3C09-9C42-4A94-A989-90715B6963A0 wds:Q58024649-38E2F602-1DE0-4BB8-B740-9612E0867F56 wds:Q58024649-3B2CDB2A-5C2F-4A95-92B4-6971771A6EB1 wds:Q58024649-5D1637BF-F16E-42D5-A335-C500257EB64D wds:Q58024649-888D8EEB-9BC7-41BA-9725-CC96C5751C0C wds:Q58024649-8C0C2ECD-DD8F-4CB6-A0AE-7A27AF7C8ECB wds:Q58024649-90318E95-2001-4D31-B1B8-2918DC0CD5DA wds:Q58024649-A2EE6E7C-58BB-4656-A031-5849BBD732F9 wds:Q58024649-A4F735C2-6ACC-4EC7-8FBF-A5654C98E73C wds:Q58024649-DC2AFE0E-6AAB-4B1B-B2CD-FEFC34641D7C wds:Q58024649-DC8FBDBF-BA26-49BD-B858-C56390B34484 wds:Q58024649-E1AC7A21-61C3-4C8A-9930-F22029F9AF12 wds:Q58024649-E764D9BD-C868-45E7-BB79-784BAC5191B3 wds:Q58024649-EEDB0C34-BF2D-4344-94D5-72E1559939CE
author name string	Peter Hersey Richard Kefford Amita Patnaik Omid Hamid Caroline Robert Scot Ebbinghaus Robert Iannone Adil Daud Wen-Jen Hwu Hassane M. Zarour Soonmo Peter Kang Jeffrey S. Weber Anthony M. Joshua Roxana Stefania Dronca Kevin Gergich Xiaoyun (Nicole) Li
rdfs:label	Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (nl) Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL) (en)
skos:prefLabel	Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (nl) Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL) (en)
name	Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (nl) Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL) (en)
author	wds:Q58024649-0711B306-DC14-45CD-9800-92D133460A5C wds:Q58024649-4041AA62-D3B1-4C3F-A8AD-660D325B1E6A wds:Q58024649-58BCDBE3-E45F-4041-9E1B-8E596A6E6801 wds:Q58024649-7C055BCF-70F3-4B46-A577-423E532F44DB
author	Antoni Ribas F Stephen Hodi Tara C Gangadhar Jedd D. Wolchok
title	wds:Q58024649-BC7059CD-C39B-4C78-A59B-C548FCB4F94B
title	Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL) (en)
page(s)	wds:Q58024649-9A38C87C-4A9F-434A-B02E-6369BAF398A8
page(s)	LBA9000-LBA9000
instance of	wds:Q58024649-330AEECD-B754-48EF-8379-6A54255782DB
instance of	scholarly article
main subject	wds:Q58024649-B24CAFD8-4F6D-472A-8BFC-90827316CCEF
main subject	antibody
published in	wds:Q58024649-92164BB6-EC78-4819-80D4-232D9DA4F40B
published in	Journal of Clinical Oncology
issue	wds:Q58024649-FC9358F0-B341-48F2-AC2B-499CF855F610
volume	wds:Q58024649-42DF42CB-51CE-4AC0-83E9-AC5E1D4B7669
issue	18_suppl
volume	32
DOI	wds:Q58024649-C0D9BCED-D47B-4444-B4CC-D69596297F65
DOI	http://dx.doi.org/10.1200/JCO.2014.32.18_SUPPL.LBA9000
DOI	10.1200/JCO.2014.32.18_SUPPL.LBA9000
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q58024649
is cites work of	Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma. Nivolumab in melanoma: latest evidence and clinical potential No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients Interleukin-2, Ipilimumab, and Anti-PD-1: Clinical Management and the Evolving Role of Immunotherapy for the Treatment of Patients With Metastatic Melanoma Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential A Rare Case of Pembrolizumab-Induced Uveitis in a Patient with Metastatic Melanoma.
is cites work of	wds:Q38595251-EA59FB0C-DFCA-40D4-929E-C3938AE16DDF wds:Q28084942-7DEFDA1C-C70D-445E-B82F-DB80F1496175 wds:Q37456334-89D60341-AF06-46DD-8243-17E34C5CB70F wds:Q51417665-F9D8AD6C-93D2-4095-86A1-D5DB8DDB4030 wds:Q28258598-2AF7005A-57EA-4926-9900-9D7296239947 wds:Q38245356-03215ADA-C623-4EAE-AD36-3CBCD10C8FE8

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 183 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software